Assessing the ecotoxicologic hazards of a pandemic influenza medical response

Environmental Health Perspectives

Volumn 119, Issue 8, 2011, Pages 1084-1090

  Singer, Andrew C ^a   Colizza, Vittoria ^b,c,d   Schmitt, Heike ^e   Andrews, Johanna ^f   Balcan, Duygu ^g,h   Huang, Wei E ^f   Keller, Virginie D J ^a   Vespignani, Alessandro ^d,g,h   Williams, Richard J ^a  

^a CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ISI FOUNDATION   (Italy)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g INDIANA UNIVERSITY   (United States)

^h INDIANA UNIVERSITY   (United States)

Author keywords

Antibiotics; Antiviral; Bacterial pneumonia; Ecotoxicity; Epidemiologic modeling; Influenza; Pandemic; Tamiflu; Wastewater treatment plant

Indexed keywords

ANTIBIOTIC AGENT; DRINKING WATER; OSELTAMIVIR;

ARTICLE; BIOFILM; DISEASE SEVERITY; DRUG USE; ECOTOXICOLOGY; ENVIRONMENTAL IMPACT; EUTROPHICATION; FRESHWATER ENVIRONMENT; GROWTH INHIBITION; PANDEMIC INFLUENZA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RIVER; SIMULATION; UNITED KINGDOM; WASTE WATER MANAGEMENT; WASTE WATER TREATMENT PLANT; WATER CONTAMINATION; WATER QUALITY;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; ENVIRONMENTAL MONITORING; HUMANS; INFLUENZA, HUMAN; PANDEMICS; PUBLIC HEALTH; WATER POLLUTANTS, CHEMICAL;

BACTERIA (MICROORGANISMS);

EID: 79961085858     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1002757     Document Type: Article

References (53)

1. Accinelli C, Saccà ML, Fick J, Mencarelli M, Lindberg R, Olsen B. 2010. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 79(8):891-897.
2. Alighardashi A, Pandolfi D, Potier O, Pons MN. 2009. Acute sensitivity of activated sludge bacteria to erythromycin. J Hazard Mater 172(2-3):685-692.
3. Anderson RM, May RM. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK:Oxford University Press.
4. Balcan D, Colizza V, Gonçalves B, Hu H, Ramasco JJ, Vespignani A. 2009a. Multiscale mobility networks and the large scale spreading of infectious diseases. Proc Natl Acad Sci USA 106:21484-21489.
5. Balcan D, Colizza V, Singer AC, Chouaid C, Hu H, Goncalves B, et al. 2009b. Modeling the Critical Care Demand and Antibiotics Resources Needed during the Fall 2009 Wave of Influenza A(H1N1) Pandemic. PLoS Curr; doi:10.1371/currents.RRN1133 [Online 8 December 2009].
6. Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, Ramasco J, et al. 2009c. Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. BMC Med 7(1):45; doi:10.1186/1741-7015-7-45 [Online 10 September 2009].
7. Bartels P, von Tümpling W Jr. 2008. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci Total Environ 405(1-3):215-225.
8. CDC (U.S. Centers for Disease Control and Prevention). 2009. Interim Guidance for Use of 23-Valent Pneumococcal Polysaccharide Vaccine during Novel Influenza A (H1N1) Outbreak. Available: http://www.cdc.gov/h1n1flu/guidance/ppsv_h1n1.htm/?date=061109 [accessed 22 February 2011].
9. CDC (U.S. Centers for Disease Control and Prevention). 2010. 2009 H1N1 Flu. Available: http://www.cdc.gov/H1N1FLU/ [accessed 22 February 2011].
10. Chien Y-W, Klugman KP, Morens DM. 2010. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 202(11):1639-1648.
11. Colizza V, Barrat A, Barthelemy M, Valleron A-J, Vespignani A. 2007. Modeling the woldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med 4(1):e13; doi:10.1371/journal.pmed.0040013 [Online 23 January 2007].
12. Cooper BS, Pitman RJ, Edmunds WJ, Gay NJ. 2006. Delaying the international spread of pandemic influenza. PLoS Med 3(6):e212; doi:10.1371/journal.pmed.0030212 [Online 2 May 2006].
13. De Zwart D, Posthuma L. 2005. Complex mixture toxicity for single and multiple species: proposed methodologies. Environ Toxicol Chem 24(10):2665-2676.
14. Djordjevic D, Wiedmann A, McLandsborough LA. 2002. Microtiter plate assay for assessment of Listeria monocytogenes biofilm formation. Appl Environ Microbiol 68(6):2950-2958.
15. Escher BI, Bramaz N, Lienert J, Neuwoehner J, Straub JO. 2010. Mixture toxicity of the antiviral drug Tamiflu (oseltamivir ethylester) and its active metabolite oseltamivir acid. Aquat Toxicol 96(3):194-202.
16. EUCAST (European Committee on Antimicrobial Susceptibility Testing). 2009. Antimicrobial Wild Type Distributions of Microorganisms. Available: http://wwweucastorg/clinical_breakpoints/ [accessed 22 February 2011].
17. European Chemicals Agency. 2008. Guidance on Information Requirements and Chemical Safety Assessment-Chapter R.10: Characterisation of Dose [Concentration]-Response for Environment. Available: http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r10_en.pdf?vers=20_08_08 [accessed 1 June 2011].
18. Even S, Poulin M, Mouchel J-M, Seidl M, Servais P. 2004. Modelling oxygen deficits in the Seine River downstream of combined sewer overflows. Ecol Model 173(2-3):177-196.
19. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic. Nature 442(7101):448-452.
20. Flusurvey.org.uk. 2010. Flusurvey Homepage. Available: http://www.flusurvey.co.uk/ [accessed 22 February 2011].
21. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. 2009. Pandemic potential of a strain of Influenza A (H1N1): early findings. Science 324(5934):1557-1561.
22. Germann TC, Kadau K, Longini IM Jr, Macken CA. 2006. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103(15):5935-5940.
23. Health Protection Agency. 2009. Pandemic (H1N1) 2009 in England: An Overview of Initial Epidemiological Findings and Implications for the Second Wave. Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1258560552857 [accessed 1 June 2011].
24. Hutchinson TH, Beesley A, Frickers PE, Readman JW, Shaw JP, Straub JO. 2009. Extending the environmental risk assessment for oseltamivir (Tamiflu®) under pandemic use conditions to the coastal marine compartment. Environ Int 35(6):931-936.
25. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163(14):1667-1672.
26. Kelleher SL, Dempsey MJ. 2007. The Effect of Oseltamivir Carboxylate on Nitrification of Wastewater by Bioparticles from a Pilot-Scale Expanded Bed Reactor. Available: http://www.scribd.com/doc/33746728/The-effect-of-oseltamivir-carboxylate-on-nitrification-of-wastewater-by-bioparticles-from-a-pilot-scale-expanded-bed-reactor-poster [accessed 22 February 2011].
27. Keller VD, Young AR. 2004. Development of the Integrated Water Resources and Water Quality Modelling System. Science Report P2-248/SR. Bristol, UK:Environment Agency.
28. Knapp CW, Dolfing J, Ehlert PAI, Graham DW. 2009. Evidence of increasing antibiotic resistance gene abundances in archived soils since 1940. Environ Sci Technol 44(2):580-587.
29. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. 2009. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 14(5). Avaiable: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19112 [accessed 2 June 2011].
30. Leroux-Roels I, Leroux-Roels G. 2009. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8:401-423.
31. Lim WS. 2007. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Thorax 62(suppl 1):1-46.
32. Louvet JN, Giammarino C, Potier O, Pons MN. 2010a. Adverse effects of erythromycin on the structure and chemistry of activated sludge. Environ Pollut 158(3):688-693.
33. Louvet J-N, Heluin Y, Attik G, Dumas D, Potier O, Pons M-N. 2010b. Assessment of erythromycin toxicity on activated sludge via batch experiments and microscopic techniques (epifluorescence and CLSM). Process Biochem 45:1787-1794.
34. Merrett S. 2007. The Thames catchment: a river basin at the tipping point. Water Policy 9(4):393-404.
35. Mills CE, Robins JM, Lipsitch M. 2004. Transmissibility of 1918 pandemic influenza. Nature 432(7019):904-906.
36. O'Toole GA, Kolter R. 1998. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol 28(3):449-461.
37. Parker D, Soong G, Planet P, Brower J, Ratner AJ, Prince A. 2009. The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infec Immun 77(9):3722-3730.
38. PREPARE Initiative. 2009. Policy Briefing: Will the Medicines Used in a Flu Pandemic Mean That Sewage Treatment Plants Do Not Work Properly? Available: http://www.prepare.org.uk/wp-content/uploads/2010/09/PREPARE-Policy-Briefing.pdf [accessed 22 February 2011].
39. Rowney NC, Johnson AC, Williams RJ. 2009. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 28(12):2733-2743.
40. Saccà ML, Accinelli C, Fick J, Lindberg R, Olsen B. 2009. Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75(1):28-33.
41. Singer AC, Howard BM, Johnson AC, Knowles CJ, Jackman S, Accinelli C, et al. 2008. Meeting report: risk assessment of Tamiflu use under pandemic conditions. Environ Health Perspect 116:1563-1567.
42. Singer AC, Nunn MA, Gould EA, Johnson AC. 2007. Potential risks associated with the widespread use of Tamiflu. Environ Health Perspect 115:102-106.
43. Slater FR, Singer AC, Turner S, Barr JJ, Bond PL. 2011. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu®) and loss of nutrient removal performance. FEMS Microbiol Lett 315(1):17-22.
44. Smith DL, Harris AD, Johnson JA, Silbergeld EK, Morris JG Jr. 2002. Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. Proc Natl Acad Sci USA 99(9):6434-6439.
45. Söderström H, Järhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. 2009. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 4(6):e6064; doi:10.1371/journal.pone.0006064 [Online 26 June 2009].
46. Soong G, Muir A, Gomez MI, Waks J, Reddy B, Planet P, et al. 2006. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest 116(8):2297-2305.
47. Straub JO. 2009. An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza-and pandemic-use conditions. Ecotoxicol Environ Saf 72:1625-1634.
48. UK Department of Health. 2007. The Use of Antibiotics for Pandemic Influenza: Scientific Evidence Base. Available: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_077274.pdf [accessed 22 February 2011].
49. UK Department of Health. 2009. Swine Flu: UK Planning Assumptions. Available: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_104844 [accessed 22 February 2011].
50. Williams RJ, Keller VDJ, Johnson AC, Young AR, Holmes MGR, Wells C, et al. 2009. A national risk assessment for intersex in fish arising from steroid estrogens. Environ Toxicol Chem 28(1):220-230.
51. World Health Organization. 2009. Pandemic (H1N1) 2009. Available: http://www.who.int/csr/disease/swineflu/en/ [accessed 22 February 2011].
52. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, et al. 2009. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 326(5953):729-733.
53. Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, et al. 2010. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 341:341:c4779; doi: 10.1136/bmj.c4779 [Online 28 September 2010].